Cargando…

Antibody response to a third booster dose of SARS-CoV-2 vaccination in adults with haematological and solid cancer: a systematic review

BACKGROUND: Patients living with cancer are at a significantly increased risk of morbidity and mortality after infection with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). This systematic review aims to investigate the current available evidence about the immunogenicity of SARS-CoV-2...

Descripción completa

Detalles Bibliográficos
Autores principales:	Al Hajji, Youssra, Taylor, Harriet, Starkey, Thomas, Lee, Lennard Y. W., Tilby, Michael
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9555704/ https://www.ncbi.nlm.nih.gov/pubmed/36224402 http://dx.doi.org/10.1038/s41416-022-01951-y

Ejemplares similares

COVID-19: Third dose booster vaccine effectiveness against breakthrough coronavirus infection, hospitalisations and death in patients with cancer: A population-based study
por: Lee, Lennard Y.W., et al.
Publicado: (2022)

Safety of third SARS-CoV-2 vaccine (booster dose) during pregnancy
por: Dick, Aharon, et al.
Publicado: (2022)

The third booster vaccination dose against COVID-19: indication for circulating SARS-CoV-2 variants
por: Rahimi, Farid, et al.
Publicado: (2021)

Third primary SARS-CoV-2 mRNA vaccines enhance antibody responses in most patients with haematological malignancies
por: Cook, Lucy B., et al.
Publicado: (2022)

Third BNT162b2 Vaccine Booster Dose against SARS-CoV-2-Induced Antibody Response among Healthcare Workers
por: Hussein, Khetam, et al.
Publicado: (2022)

Booster doses of COVID-19 vaccines for patients with haematological and solid cancer: a systematic review and individual patient data meta-analysis
por: Mai, Aaron Shengting, et al.
Publicado: (2022)

Booster effect of the third dose of SARS-CoV-2 mRNA vaccine in Japanese kidney transplant recipients
por: Kawabe, Mayuko, et al.
Publicado: (2023)

Antibody response to SARS-CoV-2 booster vaccines
por: Loving, Hanna S., et al.
Publicado: (2022)

Safety and immunogenicity of the third (booster) dose of inactivated and recombinant protein SARS-CoV-2 vaccine for patients with endocrine-related cancer
por: Han, Shanshan, et al.
Publicado: (2023)

IgG level of the third booster dose for mRNA of SARS-CoV-2 vaccines among Iraqi healthcare workers
por: Rasheed, Waleed S., et al.
Publicado: (2023)

A Third Dose of SARS-CoV-2 Vaccine Increases Neutralizing Antibodies Against Variants of Concern in Solid Organ Transplant Recipients
por: Karaba, Andrew H., et al.
Publicado: (2021)

A third dose of SARS-CoV-2 vaccine increases neutralizing antibodies against variants of concern in solid organ transplant recipients
por: Karaba, Andrew H., et al.
Publicado: (2022)

Comparison of SARS-CoV-2 Antibody Levels after a Third Heterologous and Homologous BNT162b2 Booster Dose
por: Gareayaghi, Nesrin, et al.
Publicado: (2022)

Previous SARS‐CoV‐2 infection or a third dose of vaccine elicited cross‐variant neutralising antibodies in vaccinated solid‐organ transplant recipients
por: Chang, Chih‐Chao, et al.
Publicado: (2022)

Sars-Cov-2 Antibody Levels in Blood Cancer Patients after a Third Sars-Cov-2 “Booster” Vaccination - Observational Data from the LLS National Registry
por: Greenberger, Lee M, et al.
Publicado: (2021)

Booster dose of mRNA vaccine augments waning T cell and antibody responses against SARS-CoV-2
por: Özbay Kurt, Feyza Gül, et al.
Publicado: (2022)

Humoral Effect of SARS-CoV-2 mRNA vaccination with booster dose in solid tumor patients with different anticancer treatments
por: Piubelli, Chiara, et al.
Publicado: (2023)

A third (booster) dose of the inactivated SARS-CoV-2 vaccine elicits immunogenicity and T follicular helper cell responses in people living with HIV
por: Lv, Zhengchao, et al.
Publicado: (2023)

SARS-COV-2 antibodies after booster vaccination. Identification of subgroups with poor response
por: Ayuso García, B., et al.
Publicado: (2023)

Impact of maternal SARS-CoV-2 booster vaccination on blood and breastmilk antibodies
por: Rick, Anne-Marie, et al.
Publicado: (2023)

Potent antibody immunity to SARS‐CoV‐2 variants elicited by a third dose of inactivated vaccine
por: Ju, Bin, et al.
Publicado: (2022)

Antibody response to a third dose of SARS‐CoV‐2 vaccine in heart and lung transplant recipients
por: Alejo, Jennifer L., et al.
Publicado: (2022)

Strong Correlations between the Binding Antibodies against Wild-Type and Neutralizing Antibodies against Omicron BA.1 and BA.2 Variants of SARS-CoV-2 in Individuals Following Booster (Third-Dose) Vaccination
por: Suntronwong, Nungruthai, et al.
Publicado: (2022)

Comparative analysis of COVID-19 vaccine responses and third booster dose-induced neutralizing antibodies against Delta and Omicron variants
por: Belik, Milja, et al.
Publicado: (2022)

Comparison of the Effectiveness and Safety of Heterologous Booster Doses with Homologous Booster Doses for SARS-CoV-2 Vaccines: A Systematic Review and Meta-Analysis
por: Deng, Jie, et al.
Publicado: (2022)

Third Early “Booster” Dose Strategy in France of bnt162b2 SARS-CoV-2 Vaccine in Allogeneic Hematopoietic Stem Cell Transplant Recipients Enhances Neutralizing Antibody Responses
por: Ahmed-Belkacem, Abdelhakim, et al.
Publicado: (2022)

A third dose of inactivated SARS-CoV-2 vaccine induces robust antibody responses in people with inadequate response to two-dose vaccination
por: Zhou, Taicheng, et al.
Publicado: (2022)

Third trimester messenger RNA COVID-19 booster vaccination upsurge maternal and neonatal SARS-CoV-2 immunoglobulin G antibody levels at birth
por: Kugelman, Nir, et al.
Publicado: (2022)

Serological study of CoronaVac vaccine and booster doses in Chile: immunogenicity and persistence of anti-SARS-CoV-2 spike antibodies
por: Vargas, Leonardo, et al.
Publicado: (2022)

Dynamics of SARS-CoV-2 Antibody Response to CoronaVac followed by Booster Dose of BNT162b2 Vaccine
por: Fonseca, Marcela Helena Gambim, et al.
Publicado: (2022)

Anti-SARS-CoV-2 inactivated vaccine in patients with ANCA-associated vasculitis: Immunogenicity, safety, antibody decay and the booster dose
por: Pereira, Rosa M.R., et al.
Publicado: (2022)

Prospective longitudinal analysis of antibody response after standard and booster doses of SARS-COV2 vaccination in patients with early breast cancer
por: Kim, Jinyong, et al.
Publicado: (2022)

Comparison of vaccine-induced antibody neutralization against SARS-CoV-2 variants of concern following primary and booster doses of COVID-19 vaccines
por: Hvidt, Astrid K., et al.
Publicado: (2022)

SARS-CoV2 vaccine boosters for India
por: Kang, Gagandeep
Publicado: (2022)

Kinetics of the Antibody Response to Boostering With Three Different Vaccines Against SARS-CoV-2
por: Markewitz, Robert, et al.
Publicado: (2022)

Antibody and T-cellular response to COVID-19 booster vaccine in SARS-CoV-1 survivors
por: Lu, Bi-Nan, et al.
Publicado: (2022)

Booster vaccinations and Omicron: the effects on SARS-CoV-2 antibodies in Dutch blood donors
por: Quee, F. A., et al.
Publicado: (2023)

Antibody response following the third and fourth SARS-CoV-2 vaccine dose in individuals with common variable immunodeficiency
por: Nielsen, Bibi Uhre, et al.
Publicado: (2022)

Antibody Titers After a Third and Fourth SARS-CoV-2 Vaccine Dose in Bizen City, Japan
por: Kadowaki, Tomoka, et al.
Publicado: (2023)

Antibody induction and immune response in nasal cavity by third dose of SARS-CoV-2 mRNA vaccination
por: Ishizaka, Aya, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_cik3pam45vutfjg0j0lokgpipu